

Market Announcement

20 June 2022

Zelira Therapeutics Limited (ASX: ZLD) – Trading Halt

Description

The securities of Zelira Therapeutics Limited ('ZLD') will be placed in trading halt at the request of ZLD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 22 June 2022 or when the announcement is released to the market.

Issued by

Oma Murad

Adviser, Listings Compliance (Perth)

20 June 2022

Australian Securities Exchange Limited
40 Central Park
152 – 158 St Georges Terrace
PERTH WA 6000

Attention: Barbara Lim
By email only: Barbara.Lim@asx.com.au

Dear Madam,

TRADING HALT REQUEST

In accordance with ASX Listing Rule 17.1, Zelira Therapeutics Limited ('the Company', ASX: **ZLD**) requests the granting of a trading halt in ZLD's ordinary securities listed on the Australian Securities Exchange (ASX).

The Company provides the following information in relation to the request:

1. The trading halt is requested pending an announcement by the Company in relation to its Scheme Implementation Deed;
2. The Company requests an immediate trading halt and anticipates that the trading halt remain in place until the earlier of the commencement of trading on Wednesday, 22 June 2022 or the making of an announcement in respect to its Scheme Implementation Deed; and
3. ZLD confirms that it is not aware of any reason why a trading halt should not be granted or any other information necessary to inform the market about the trading halt.

Yours sincerely



Tim Slate
Company Secretary

For further information please contact:

Company

Dr Oludare Odumosu
Managing Director & CEO
T: +1 909 855 0675
E: oodumosu@zeliratx.com

Investors

Ronn Bechler
Executive Chairman, Market Eye
T: +61 400 009 774
E: ronn.bechler@marketeye.com.au

About Zelira Therapeutics (www.zeliratx.com)

Australia

Level 3
101 St Georges Terrace
Perth WA 6000
AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeliratx.com
W: www.zeliratx.com
ACN 103 782 378

USA

5110 Campus Drive
Suite 150
Plymouth Meeting, PA
19462
UNITED STATES OF AMERICA
Tel: +1 484-630-0650

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is a leading global biopharmaceutical company in the research, development and commercialisation of clinically-validated cannabinoid medicines. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to access the world's largest and fastest growing markets. The Company is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain. The Company has two proprietary formulations under the HOPE® brand that are generating revenues in Australia, Pennsylvania, Louisiana and Washington D.C. with other states in the US expected to follow. Zelira is also generating revenue in Australia from its proprietary and patented Zenivol® - a leading cannabinoid-based medicine for treatment of chronic insomnia. Zenivol® has successfully completed the first Phase 1b/2a clinical trial for chronic insomnia where it was found to be a safe and effective treatment. This clinical trial is published in the prestigious journal 'Sleep'. In 2020, Zelira partnered with SprinJene®Natural to develop and commercialise natural and organic oral care products under the SprinjeneCBD brand, as part of Zelira's OTC business. The SprinjeneCBD toothpaste product is the first of several scientifically formulated, hemp-derived, oral care products containing cannabinoids and based on the proprietary and patented technology of Blackseed oil and Zinc.

The Company conducts its work in partnership with world-leading researchers and organizations which since inception includes Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.